Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Protective Effects of Pioglitazone in Renal Ischemia–Reperfusion Injury (Riri): Focus on Oxidative Stress and Inflammation Publisher Pubmed



Golmohammadi M1 ; Ivraghi MS2 ; Hasan EK3 ; Huldani H4 ; Zamanian MY5, 6, 7 ; Rouzbahani S8, 9 ; Mustafa YF10 ; Alhasnawi SS11 ; Alazbjee AAA12 ; Khalajimoqim F7 ; Khalaj F13
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 1988873554, Iran
  2. 2. School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
  3. 3. College of Pharmacy, Al-Bayan University, Baghdad, Iraq
  4. 4. Department of Physiology, Faculty of Medicine Lambung, Mangkurat University, South Kalimantan, Banjarmasin, Indonesia
  5. 5. Urology and Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
  6. 6. Department of Physiology, Hamadan University of Medical Sciences, Hamadan, 6718773654, Iran
  7. 7. Department of Pharmacology and Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, 6718773654, Iran
  8. 8. Miller School of Medicine, Bascom Palmer Eye Institute, University of Miami, Miami, FL, United States
  9. 9. Department of Community Medicine and Family Physician, School of Medicine, Isfahan University of Medical Sciences, Hezar Jarib Blvd, Isfahan, Iran
  10. 10. Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq
  11. 11. College of Pharmacy, the Islamic University, Najaf, 54001, Iraq
  12. 12. College of Medicine, Al-Ayen University, Thi-Qar, Iraq
  13. 13. Digestive Diseases Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Clinical and Experimental Nephrology Published:2024


Abstract

Background: Renal ischemia-reperfusion injury (RIRI) is a critical phenomenon that compromises renal function and is the most serious health concern related to acute kidney injury (AKI). Pioglitazone (Pio) is a known agonist of peroxisome proliferator-activated receptor-gamma (PPAR-γ). PPAR-γ is a nuclear receptor that regulates genes involved in inflammation, metabolism, and cellular differentiation. Activation of PPAR-γ is associated with antiinflammatory and antioxidant effects, which are relevant to the pathophysiology of RIRI. This study aimed to investigate the protective effects of Pio in RIRI, focusing on oxidative stress and inflammation. Methods: We conducted a comprehensive literature search using electronic databases, including PubMed, ScienceDirect, Web of Science, Scopus, and Google Scholar. Results: The results of this study demonstrated that Pio has antioxidant, anti-inflammatory, and anti-apoptotic activities that counteract the consequences of RIRI. The study also discussed the underlying mechanisms, including the modulation of various pathways such as TNF-α, NF-κB signaling systems, STAT3 pathway, KIM-1 and NGAL pathways, AMPK phosphorylation, and autophagy flux. Additionally, the study presented a summary of various animal studies that support the potential protective effects of Pio in RIRI. Conclusion: Our findings suggest that Pio could protect the kidneys from RIRI by improving antioxidant capacity and decreasing inflammation. Therefore, these findings support the potential of Pio as a therapeutic strategy for preventing RIRI in different clinical conditions. Graphical abstract: Pioglitazone (Pio) plays a protective role in renal ischemia–reperfusion injury (RIRI) by regulating oxidative stress and inflammation responses. In an animal model of RIRI, Pio reduced inflammation, and oxidative stress renal tubule damage through several cellular pathways. It also promotes cell viability and inhibits autophagy. Pioe targets various pathways such as TNF-α, NF-κB signaling systems, KIM-1 and NGAL pathways, and AMPK phosphorylation. (Figure presented.) © The Author(s), under exclusive licence to Japanese Society of Nephrology 2024.